Moringa Leaf Powder Export Feasibility Check (De)

Tridge 데이터와 무관한 제품·시장 본질 적합도

Confirmed from the brief: the seller is India-based, export-ready rather than experienced, and the offer includes both moringa leaf powder and finished capsule/tablet forms for nutraceutical distribution. Confirmed through research directionally that Egypt and Asian markets for supplements are compliance-sensitive and likely require importer-side registration, label adaptation, and claims control, but I could not secure robust official public documents or citable import-demand figures for moringa supplements within this run. I also could not verify market-specific tariff treatment or whether each target Asian country accepts moringa uniformly as a supplement ingredient. Therefore the main confidence is on regulatory complexity, not on publicly cited demand statistics.

수출 난이도 (규제·무역·인증)

This request is intrinsically difficult because the offer spans both a raw botanical powder and finished capsule/tablet nutraceutical forms, and finished ingestible supplements usually face more paperwork than bulk ingredients. For Egypt, a first shipment should expect local importer-led product compliance work, Arabic retail-label adaptation, and careful control of disease/therapeutic claims; I could not fully verify the exact current NFSA/CAPA procedural document within the research budget, so those steps are stated conservatively. For the broad 'Asia' scope, requirements are not harmonized: some markets treat health supplements under notification/registration systems with ingredient-permissibility checks, while others scrutinize botanical claims, excipients, and dosage-form GMP documentation. I could not verify a corridor-wide tariff advantage for India, nor country-by-country acceptance rules for moringa as an allowed supplement ingredient across Asia, so market entry should be sequenced country by country rather than treated as one regional launch.

시장 특성

구매자 우위 시장

특이사항

With the seller positioned in a common-origin herbal-supplement supply base, distributors are likely to compare multiple Indian and regional offers on price, documentation quality, and claim safety. Finished moringa dosage forms are more exposed to private-label competition and buyer requests for low MOQs, stability data, and clean documentation than bulk powder. The undefined 'Asia' target materially increases execution risk because each country may apply different rules on botanicals, claims, and retail labeling.

Pool → Targeted(20%) → Responded → Lead funnel. Responded·Lead는 본질 난이도 가중(low ×1.2 · moderate ×1.0 · high ×0.7). 최종 적합도는 Lead 범위 기준. Pool은 현재 매칭 기준 최소치이며 추가 발굴이 가능합니다(+).

Tridge discovery coverage is broad enough to surface real buyer opportunities for this request on axis ②: total pool 71206 → targeted 13502.8, with expected leads at 4.9~29.6 in the conservative scenario and 29.6~103.6 in the aggressive scenario. The lead yield is not evenly distributed, however; South Asia nutraceutical distributors carries the largest reachable upside, while several Egypt- and Asia-wide high-difficulty universes remain small-yield despite meaningful pool counts. There is a clear intrinsic-vs-reach gap: axis ① is low because the offer is compliance-heavy and spans both bulk ingredient and finished supplement forms, but axis ② itself is not weak because Tridge can still discover and activate sizeable buyer universes, especially in South Asia and selected Southeast Asia channels. Even so, a large pool should not be read as 1:1 deal potential, since the actual deliverable opportunity is the lead band after difficulty-weighted funnel loss.

AI 리서치 기반 회사 수출 역량 진단 — 관측 무역 데이터는 참고 지표 (특정 제품/시장 적합성은 아래 별도 표시)

무역 데이터 미매칭 — 진술 정보 기반 평가

Web research on the company name provided, “De” in India, did not yield a reliably identifiable company profile, website, corporate listing, export team signal, overseas office, exhibition history, or export-related certifications; with a two-letter name, the public footprint is too ambiguous to verify specific export operations. The reference trade data is NO MATCH, which is not evidence of no exports; Tridge에서 관측된 수출 데이터가 없다는 가정 하의 진단이며, 이는 실제로 수출한 적이 없다는 의미가 아니라 관측 커버리지 밖 수출이 존재할 수 있어 실제와 차이가 있을 수 있다. Applying the direct-export standard, I could not confirm signs of a systematized export organization such as dedicated overseas sales staff, multi-market direct business development, or documented regulatory/commercial execution. Given the skeptical baseline and the lack of verifiable evidence that this company itself already runs export as an organized function, the assessment remains low.

캠페인 가격 · 커밋 Lead

결정론적 산정 — AI가 아닌 시스템 룰

확약 = min(4축 점수 밴드, pool 이행 상한). 4축 = 제품·시장 적합도(high 3 · moderate 2 · low 0) + 수출 난이도(low 3 · moderate 2 · high 0) + 판매자 경쟁력(high 2 · moderate 1 · low 0 · 미제공 1) + Tridge 데이터 준비도(±1). 밴드 8+→5 · 6~7→4 · 4~5→3 · 2~3→2 · 그 외 1. 상한은 보수·공격 시나리오 Lead 상한의 중간값(중복 제거 union pool 기준). 커밋 0개는 판매 비권고에서만.

Tridge 데이터 준비도: 발굴 pool 중 수입 실적이 확인되는 비율 52.7% — 나머지는 이름·설명 매칭만으로 잡힌 미검증 회사다.

Committed lead count is 0 because the fixed system verdict must be narrated as given: 4축 확약 점수 1 → 목표 1건, 발굴 pool 67514개 기준 이행 상한 5건, 둘 중 낮은 값이 확약이 된다. In this case, the number was held down by the grades rather than the pool cap: 제품·시장 적합도 low (+0), 수출 난이도 high (+0), 판매자 수출 경쟁력 low (+0), and only Tridge 데이터 준비도 52.7% (+1) contributed, resulting in 확약 점수 1 → 목표 1건. Because the system-computed committed_leads_count is fixed at 0, this campaign should be communicated with very conservative expectation setting despite the large discovery pool. The binding issue here is not lack of discoverable buyers, but weak overall campaign readiness across the assessed axes.